Loading...

PR Information Data

AdipoLABs receives 'Industrial Grand Prize for 3 consecutive years' : 2019.03.08
19-03-08 15:57 4,420회 0건

한성호 아디포랩스 대표(사진 오른쪽)가 '신기술대상 3년 연속상'을 수상한 뒤 박종면 머니투데이 대표와 기념사진을 찍고 있다/사진=중기협력팀 오지훈 기자

Han Sung-ho, CEO of AdipoLABs (right side) receives the 'New Technology Grand Prize for 3 consecutive years' and is taking a commemorative photo with Money Today News CEO Park Jong-myeon.


AdipoLABs is a company that developed “REMISSION 1℃”, a high-frequency hyperthermia cancer treatment device using purely domestic technology. REMISSION 1℃ is licensed by the Ministry of Food and Drug Safety(KFDA) and got USFDA registration. In addition, they have obtained certifications such as Halal, ISO 13485, Shariah compliance, and RoHS. In particular, many domestic and foreign hospitals use this product. In Korea, Catholic University Seoul St. Mary's Hospital is using, while overseas, the Oxymed Hospital (India) and the Gulistan National Cancer Center (Uzbekistan) are using REMISSION 1℃”. Currently, there are a lot of inquiries about product introduction in overseas markets.

The '2019 5th Korea Industry Awards' award ceremony hosted by Money Today News was held at the press center in Jung-gu, Seoul on the afternoon of 8th. AdipoLABs (CEO Han Sung-ho) won the 'New Technology Grand Prize for three consecutive years' at the event.